Update on Amgen’s bemarituzumab Phase 1b/3 FORTITUDE-102 Study
Amgen, Zai Lab’s partner and study sponsor, announced during its Q3 2025 earnings call on November 4, 2025, that the Phase 1b/3 FORTITUDE-102 trial evaluating bemarituzumab plus chemotherapy and nivolumab in patients with first-line gastric cancer was stopped for inadequate efficacy, at an ad hoc analysis requested by the data monitoring committee.
We will continue to work closely with Amgen and provide further updates as appropriate.
For more information, please contact:
Investor Relations:
Christine Chiou / Cyan Liu
+1 (917) 886-6929 / +86 195 3130 8895
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com
Media:
Shaun Maccoun/ Xiaoyu Chen
+1 (857) 270-8854 / +86 185 0015 5011
shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com